The detection of the Janus kinase 2 (JAK2) mutation V617F (JAK2 mutV617F ) has become fundamental in the differential diagnosis of myeloproliferative neoplasms (MPNs), particularly polycythemia vera (X90% of cases), essential thrombocythemia and chronic idiopathic myelofibrosis (50-70% cases of each). 1 Although several studies addressing the JAK2 genotype in MPN as well as the hematopoietic progenitors targeted by JAK2 mutation and the frequency of this event based on molecular analyses of purified bone marrow cell populations (both myeloid and lymphoid) have already been published, [2] [3] [4] there is to date no published technique for the morphological identification of JAK2 mutV617F positive cells in MPN. Therefore, in this study, we describe a novel JAK2 mutV617F -specific in situ PCR (JAK2 mutV617F isPCR) using an optimized isPCR technique 5 on formalin-fixed and decalcified bone marrow samples (fixation 24-48 h in 4% buffered formalin solution, decalcification 24 h in 0.5 M EDTA disodium salt/ 0.5 M NaOH solution, pH 7.2). Allele-specific (AS) PCR amplification was carried out as conventional solution-based as well as in situ as described, 5-7 using a JAK2 mutV617F forward oligonucleotide primer (JAK2 mutV617F forward 5 0 -TTT TAA ATT ATG GAG TAT GTT-3 0 (the underlined final base anneals at the site of the GXT mutation) and an unmutated forward JAK2 primer as wild-type control (JAK2 unmutated forward 5 0 -TTT TAA ATT ATG GAG TAT GTG-3 0 ) in combination with a reverse primer annealing downstream of the JAK2 mutV617F mutation (JAK2 reverse 5 0 -GTT TAC ACT GAC ACC TAG CTG-3 0 ). Initially, the specificity of the conventional JAK2 mutV617F AS-PCR was analyzed using sample material from JAK2 mutV617F -positive (n ¼ 68) and -negative (n ¼ 62) cases of MPN that had previously been identified using direct sequencing 8 as well as in DNA from normal tissue samples (n ¼ 21). All JAK2 mutV617F -positive MPN showed specific PCR products in conventional JAK2 mutV617F AS-PCR experiments, whereas no amplificates were detectable in unmutated DNA samples from JAK2 mutV617F -negative MPN or in DNA from normal tissue samples (Figure 1 ). However, in one tissue sample that had previously been diagnosed as JAK2 mutV617F -negative ET (Figure 2a ), a weak specific PCR product was detected using solution based JAK2 mutV617F AS-PCR (Figure 1 ), lane 3. Reanalysis of this sample using direct sequencing with a reduced background reaction identified a JAK2 mutV617F mutation of B5% (calculated as the percentage of mutant allele compared to total peak height 9 ; Figure 2b ). Owing to the fact that direct sequencing has a lower sensitivity for the detection of the JAK2 mutV617F mutation than other, more sensitive methods such as AS-PCR, restriction fragment length polymorphism (RFLP) or semiquantitative real-time PCR, 10,11 the afore described identification of a JAK2 mutV617F -positive case of MPN previously diagnosed as JAK2 mutV617F -negative MPN using JAK2 mutV617F AS-PCR is in good agreement with data showing that the sensitivity of direct sequencing is slightly lower (90-95%) than that of AS-PCR or RFLP. 10, 12 Following the experiments to determine the specificity of the conventional JAK2 mutV617F AS-PCR, the corresponding isPCR was established using paraffin sections from MPN bone marrow trephines of the same cases analyzed using solution-based AS-PCR. In isPCR, PCR products were labeled with digoxigenin and detected immunologically as described previously. 5, 7 Specific PCR products were detected in samples from all JAK2 mutV617F -positive cases of MPN (n ¼ 68), whereas specific PCR products could not be found in any of the samples from JAK2 mutV617F -negative cases of MPN (n ¼ 62) or from normal tissue (n ¼ 21; Figures 3a and b) . Moreover, in the tissue samples from JAK2 mutV617F -positive cases of MPN described above, nonhematopoietic bone marrow cells, such as endothelial cells from sinus vessels, also remained clearly negative (Figure 3a , arrows). It was found that 80-90% of hematopoietic cells showed positive staining (Figure 3a ) in JAK2 mutV617F homozygous samples as confirmed by direct sequencing and conventional AS-PCR, whereas in specimens with heterozygous/ mixed clonality concerning JAK mutV617F mutation (Figure 3b ), 10-70% of hematopoietic cells were stained positively. In both cases, erythroid and granulopoietic precursors were more commonly stained (80-100%) than megakaryocytes (30-50%; Figure 3d ). These results demonstrate that the quantity of cells showing positive digoxigenin-staining in isPCR experiments is correlated to the mutation status of JAK2 mutV617F . Moreover, our observations are in agreement with the results of previous studies, where similar percentages of JAK mutV617F -positive hematopoietic precursors were found in purified bone marrow populations using mutational analysis. 4, 13 Finally, in the case of ET mentioned above where only a small amount of mutated JAK2 DNA was detected by solution based AS-PCR (Figure 1 ), lane 3, 5-10% of hematopoietic cells were positively stained in JAK mutV617F -specific isPCR experiments (data no shown). These data demonstrate that JAK mutV617F -specific isPCR is adequate for the detection of small amounts of individual JAK mutV617F -positive cells. However, further experiments will be needed to investigate whether the sensitivity of the JAK mutV617F -specific isPCR is adequate to detect single JAK mutV617F -positive cells in tissue samples of MPNs.
The ability to identify individual cells expressing or carrying specific genes of interest in a tissue section by isPCR provides a great advantage over conventional PCR methods performed in solution for the determination of various aspects of normal, as opposed to pathological, conditions. In isPCR, the most crucial step is the fixation of the cells in a tissue sample to allow the amplification of DNA on the one hand, without, on the other hand, destroying or distorting the subcellular compartments. 5 In the method described here, bone marrow trephines were fixed in 4% buffered formalin solution, but alternative fixatives such as B5 should be compatible with our protocol, as side-by-side studies comparing B5 to formalin and mercury-free alternatives generated virtually identical results concerning immunohistochemistry, DNA extraction and in situ hybridization.
14,15 As, Letters to the Editor however, isPCR is a complex, multistep procedure that has to be optimized in each laboratory; the immunohistochemical detection of JAK2 mutated cells with antibodies specific for the mutated form of JAK2 may prove to be an alternative method for in situ analysis of these cells in future.
Nevertheless, the JAK2 mutV617F -specific isPCR described here is, to the best of our knowledge, the first isPCR identifying individual cells expressing a mutated gene product in bone marrow trephine sections with similar sensitivity and specificity as conventional genotyping. As conventional PCR does not allow the direct association of amplified gene signals with the histological cell type, the JAK2 mutV617F -specific isPCR will help to elucidate the pathogenesis of MPN with additional therapeutic and prognostic impact, such as the morphological detection of the percentage of tumor cells before and after therapy. 16 Moreover, the JAK2 mutV617F -specific isPCR may offer the opportunity to investigate the presence of JAK2 mutations in B and T cells, an issue that is still being discussed controversially in different studies. 2, 4 Finally, the principle of this technique may possibly be extended to other disease-related genetic alterations, such as the k-ras mutation in colon and lung cancers. -specific isPCR detects individual hematopoietic cells harboring the JAK2 mutV617F in MPN with a strong red nuclear staining due to the detection of incorporated DIG-labelled nucleotides by alkaline-phosphatase-coupled anti-DIG antibody 7 and subsequent fuchsin red staining. 7 By contrast JAK2 -positive bone marrow cells detected by isPCR a clear prevalence of erythroid (10-100%, average 68%) and granulopoietic (10-100%, average 56%) precursors with lower amounts of positively stained megakaryocytes (10-60%, average 38%) were detectable with similar results for the different MPN subtypes except for lower amounts of positive megakaryocytes in ET (d). DIG, digoxigenin; EP, erythropoiesis; ET, essential thrombocythemia; GP, granulopoiesis; isPCR, in situ PCR; JAK2, Janus kinase 2; MP, megakaryopoiesis; MPN, myeloproliferative neoplasm.
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